EBR Systems has reported a significant increase in commercial implantations of its WiSE System in Q1 2026, more than doubling case volumes from the previous quarter and projecting preliminary revenue between US$2.25 million and US$2.36 million.
- WiSE System implants more than doubled to 41 in Q1 2026
- Total commercial implants reached 71 during pilot and Limited Market Release phases
- Preliminary unaudited Q1 revenue estimated between US$2.25M and US$2.36M
- 16 new purchase agreements signed and 22 physicians trained in the quarter
- 1-for-10 reverse stock split implemented effective 1 April 2026
Strong Commercial Growth in Q1 2026
EBR Systems, Inc. (ASX:EBR) reported robust commercial momentum for its WiSE System during the first quarter of 2026, with implant volumes more than doubling from the previous quarter. The company successfully implanted the wireless cardiac pacing device in 41 commercial patients in Q1, bringing the total number of implants across the pilot phase and Limited Market Release to 71. This marks a notable acceleration compared to the 18 implants recorded in Q4 2025.
Alongside the increase in implantations, EBR signed 16 additional purchase agreements with target centres during the quarter, adding to the 21 agreements previously secured. The company also trained 22 new physicians, increasing the total number of trained implanting physicians to 55. These developments support the ongoing rollout of the Limited Market Release and underpin the company’s efforts to expand adoption of the WiSE System.
Preliminary Financial Results and Capital Structure Update
Based on preliminary unaudited results, EBR expects to report revenue in the range of US$2.25 million to US$2.36 million for Q1 2026. The company cautions that these figures are subject to quarter-end closing adjustments and audit review, and may differ from final reported results. No detailed information on costs or profitability was provided in the announcement.
In a notable capital structure development, EBR implemented a 1-for-10 reverse stock split effective 1 April 2026, following shareholder approval in March. The company adjusted the conversion ratio of its CHESS Depositary Interests (CDIs) from 1:1 to 10:1 without consolidating the CDIs themselves. This move aims to streamline the company’s equity structure without impacting individual ownership ratios. The reverse stock split was detailed in a prior announcement, which outlined the timetable and rationale behind the change.
Ongoing Clinical and Investor Engagement
EBR continues to advance its clinical programs, including enrolment in the WiSE-UP post-approval study and the TLC-AU feasibility study. These initiatives aim to broaden the clinical evidence base supporting the WiSE System across a wider patient population. The company also reported progress in hospital education regarding reimbursement schemes such as NTAP and TPT, which are critical to facilitating wider adoption.
Management maintained an active presence in the investment community during Q1, participating in multiple healthcare conferences across the US, Australia, and Asia, and conducting an investor roadshow in Sydney and Melbourne. An investor webinar is scheduled for 10 April 2026 to discuss the Q1 results in more detail.
These commercial and clinical advances follow a trajectory of growth seen in recent quarters, including the doubling of implants in Q4 2025 and the launch of key clinical studies, as previously reported in the company’s update on accelerated clinical trials and revenue growth. This continuity highlights EBR’s focus on disciplined execution and building a foundation for broader market adoption.
Bottom Line?
EBR Systems’ Q1 2026 results demonstrate accelerating commercial adoption of its WiSE System, though investors should await audited financials and monitor clinical progress for a fuller picture.
Questions in the middle?
- How will the final audited Q1 financial results compare with the preliminary revenue guidance?
- What impact will the reverse stock split have on liquidity and investor perception in the near term?
- How quickly can EBR expand physician training and site activations to sustain implant growth?